TruSight Oncology 500
Illumina凭着尖端的癌症基因治疗和肿瘤复发监测技术，不断加快癌症伴随诊断的探索。其开发的肿瘤复发监测系统，旨在确定一整套与癌症药物开发相关的目前可行动和新兴的生物标志物。Read More...
TruSight Oncology 500是一种新一代测序（NGS）肿瘤分析方法，可分析数百种与癌症有关的生物标记。它能够鉴定各种肿瘤类型中涉及的所有相关DNA和RNA变异。
此外，它还能准确测量关键免疫疗法生物标记：肿瘤突变负荷（TMB）和微卫星不稳定性（MSI）。
通过测试整合可节省时间、费用和样本
获得可信度高的结果
解锁免疫肿瘤学
Input Recommendations for TMB, MSI, and Small Variant Analysis with TruSight Oncology 500
Technical Note | HTML
Analysis of TMB and MSI Status with TruSight Oncology 500
Application Note | HTML
Analysis of TruSight Oncology 500 data with PierianDx Clinical Genomics Workspace Software
Brochure | PDF< 1 MB
TruSight Oncology 500 Demo Program Flyer
Brochure | PDF< 1 MB
TruSight Oncology 500 datasheet
Data Sheet | HTML
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
TruSight Oncology is a set of NGS platform reagents for the detection of cancer variants, using an enrichment-based method to simultaneously analyze DNA and RNA. Gene content is not included.
Provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer research samples.
